
Alpha Cognition Reports Positive Interim Data for ALPHA-1062 in Military Traumatic Brain Injury Model
Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG), a biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders, today announced promising interim preclinical data supporting the ongoing development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The…












